The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients

Anticancer Research

Volumn 24, Issue 3 B, 2004, Pages 1981-1985

  Begum, Farah Diba ^a   Høgdall, Claus K ^b   Kjaer, Susanne K ^a   Christensen, Lise ^b   Blaakaer, Jan ^c   Bock, Johannes E ^b   Glud, Eva ^a   Høyer Hansen, Gunilla ^b   Ring Larsen, Helmer ^b,d   Høgdall, Estrid V S ^a  

^a INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

ELISA; Ovarian cancer; Prognostic factors; suPAR

Indexed keywords

CA 125 ANTIGEN; SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR; TETRANECTIN; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; ASCITES; BODY FLUID; BREAST CANCER; BREAST METASTASIS; CANCER RECURRENCE; CANCER STAGING; CELL SURFACE; CLINICAL ARTICLE; COLORECTAL CANCER; CYST FLUID; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; MULTIVARIATE ANALYSIS; OVARY CANCER; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; AGED; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTORS, CELL SURFACE; SOLUBILITY;

EID: 3242662746     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Kjaer SK and Ewertz M: Ovarian cancer in Denmark 1943-1982. Ugeskr Læger 149: 3356-3360, 1987.
2. Kjaer SK and Storm HH: Female genital organs. Survival of Danish Cancer Patients 1943-87. I: Carstensen B, Storm HH, Schou G, eds. Suppl. 33: 107-121, 1993. APMIS, Munksgaard, Copenhagen.
3. Gøtrik JK and Hjulsager M: Cancer Incidence in Denmark 1997. 1: 1-81, 1997. Sundhedsstyrrelsen, Copenhagen.
4. Qazi F and McGuire WP: The treatment of epithelial ovarian cancer. CA Cancer J Clin 45: 88-101, 1995.
5. Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, Miller A, Park R and Major FJr: Adjuvant therapy in stage I and stage II-epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 322: 1021-1027, 1990.
6. Behrendt N, Ronne E, Ploug M, Petri T, Lober D, Nielsen LS, Schleuning WD, Blasi F, Appella E and Dano K: The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem 265: 6453-6460, 1990.
7. Behrendt N, Ploug M, Patthy L, Houen G, Blasi F and Dano K: The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J Biol Chem 266: 7842-7847, 1991.
8. Vassalli JD, Baccino D and Belin D: A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 100: 86-92, 1985.
9. Plesner T, Ploug M, Ellis V, Ronne E, Hoyer-Hansen G, Wittrup M, Pedersen TL, Tscherning T, Dano K and Hansen NE: The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils. Blood 83: 808-815, 1994.
10. Plesner T, Ralfkiaer E, Wittrup M, Johnsen H, Pyke C, Pedersen TL, Hansen NE and Dano K: Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am J Clin Pathol 102: 835-841, 1994.
11. Jardi M, Ingles-Esteve J, Burgal M, Azqueta C, Velasco F, Lopez-Pedrera C, Miles LA and Felez J: Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells. Thromb Haemost 76: 1009-1019, 1996.
12. Boyd D, Florent G, Kim P and Brattain M: Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res 48: 3112-3116, 1988.
13. Hollas W, Soravia E, Mazar A, Henkin J, Blasi F and Boyd D: Decreased urokinase receptor expression by overexpression of the plasminogen activator in a colon cancer cell line. Biochem J 285: 629-634, 1992.
14. Andreasen PA, Egelund R and Petersen HH: The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57: 25-40, 2000.
15. Pöllanen J, Stephens RW and Vaheri A: Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 57: 273-328, 1991.
16. Brünner N, Nielsen HJ, Hamers M, Christensen IJ, Thorlacius-Ussing O and Stephens RW: The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer. APMIS 107: 160-167, 1999.
17. Donadio AC, Remedi MM, Frede S, Bonacci GR, Chiabrando GA and Pistoresi-Palencia MC: Decreased expression of intercellular adhesion molecule-1 (ICAM-1) and urokinase-type plasminogen activator receptor (uPAR) is associated with tumor cell spreading in vivo. Clin Exp Metastasis 19: 437-444, 2002.
18. Wilhelm O, Weidle U, Hohl S, Rettenberger P, Schmitt M and Graeff H: Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett 337: 131-134, 1994.
19. Lutz V, Reuning U, Kruger A, Luther T, von Steinburg SP, Graeff H, Schmitt M, Wilhelm OG and Magdolen V: High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice. Biol Chem 382: 789-798, 2001.
20. Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Danø K, Brünner N and Blasi F: The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 58: 1843-1849, 1998.
21. Riisbro R, Christensen IJ, Piironen T, Greenall M, Larsen B, Stephens RW, Han C, Hoyer-Hansen G, Smith K, Brunner N and Harris AL: Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Canc Res 8: 1132-1141, 2002.
22. Fernebro E, Madsen RR, Ferno M, Brunner N, Bendahl P, Christensen IJ, Johnson A and Nilbert M: Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients. Eur J Cancer 37: 486-491, 2001.
23. Wahlberg K, Hoyer-Hansen G and Casslen B: Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer. Cancer Res 58: 3294-3298, 1998.
24. Riisbro R, Christensen IJ, Høgdall C, Brünner N and Høgdall E: Soluble urokinase plasminogen activator receptor measurements: influence of sample handling. Int J Biol Markers 16: 233-239, 2001.
25. Høgdall EVS, Høgdall CK, Christensen L, Glud E, Blaakaer J, Bock JE, Vuust J, Nørgaard-Pedersen B and Kjaer SK: Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients. Anticancer Res 22: 1859-1864, 2002.
26. Høgdall EV, Høgdall CK, Blaakaer J, Christensen L, Bock JE, Vuust J, Glud E and Kjaer SK: K-ras alterations in Danish ovarian tumour patients. From the Danish "MALOVA" ovarian cancer study. Gynecol Oncol 89: 31-36, 2003.
27. Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, Norgaard-Pedersen B and Høgdall CK: Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 98: 66-73, 2003.
28. Høgdall CK: Human tetranectin: methodological and clinical studies. APMIS Suppl 86: 1-31, 1998.
29. Høgdall CK, Høgdall EV, Hørding U, Daugaard S, Clemmensen I, Nørgaard-Pedersen B and Toftager-Larsen K: Plasma tetranectin and ovarian neoplasms. Gynecol Oncol 43: 103-107, 1991.
30. Riisbro R, Stephens RW, Brunner N, Christensen IJ, Nielsen HJ, Heilmann L and von Tempelhoff GF: Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases. Gynecol Oncol 82: 523-531, 2001.
31. Cox DR: Regression models and life tables. J Roy Stat Soc B 34: 187-220, 1972.
32. Høgdall CK, Høgdall EVS, Hørding U, Clemmensen I, Nørgaard-Pedersen B and Toftager-Larsen K: Preoperative plasma tetranectin as a prognostic marker in ovarian cancer patients. Scand J Clin Lab Invest 53: 741-746, 1993.
33. Swenerton KD, Hislop TG, Spinelli J, LeRiche JC, Yang N and Boyes DA: Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol 65: 264-270, 1985.
34. Mogensen O: Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol 44: 207-212, 1992.
35. Westergaard UB, Andersen MH, Heegaard CW, Fedosov SN and Petersen TE: Tetranectin binds hepatocyte growth factor and tissue-type plasminogen activator. Eur J Biochem 270: 1850-1854, 2003.
36. Diaz VM, Planaguma J, Thomson TM, Reventos J and Paciucci R: Tissue plasminogen activator is required for the growth, invasion, and angiogenesis of pancreatic tumor cells. Gastroenterology 122: 806-819, 2002.
37. Høgdall CK, Nørgaard-Pedersen B and Mogensen O: The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer. Anticancer Res 22: 1765-1768, 2002.
38. Deng X, Høgdall EV, Høgdall CK, Norgaard-Pedersen B, Jørgensen M, Nielsen H and Engelholm SA: The prognostic value of pretherapeutic tetranectin and CA-125 in patients with relapse of ovarian cancer. Gynecol Oncol 79: 416-419, 2000.
39. Høgdall CK, Christensen IJ, Stephens RW, Sørensen S, Nørgaard-Pedersen B and Nielsen HJ: Serum tetranectin is an independent prognostic marker in colorectal cancer and weakly correlated with plasma suPAR, plasma PAI-1 and serum CEA. APMIS 110: 630-638, 2002.
40. Chavakis T, Kanse SM, Yutzy B, Lijnen HR and Preissner KT: Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood 91: 2305-2312, 1998.
41. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F and Fazioli F: Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 15: 1572-1582, 1996.
42. Makar AP, Baekelandt M, Trope CG and Kristensen GB: The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 56: 175-180, 1995.